Ribocil-C |
| رقم الكتالوجGC32158 |
Ribocil-C هو مثبط انتقائي للغاية لمحولات الريبوفلافين البكتيرية
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1825355-56-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ribocil-C is a highly selective inhibitor of bacterial riboflavin riboswitches.
Ribocil-C is a highly selective inhibitor of the flavin mononucleotide (FMN) riboswitch that controls expression of de novo riboflavin (RF, vitamin B2) biosynthesis in Escherichia coli. Ribocil-C specifically inhibits dual FMN riboswitches, separately controlling RF biosynthesis and uptake processes essential for Staphylococcus aureus growth and pathogenesis[1]. Ribocil-C is a small-molecule synthetic mimic of FMN that binds the FMN riboswitch of multiple GN bacteria, including Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, to inhibit ribB expression, RF synthesis, and consequently arrest bacterial growth[1][2].
Higher dose Ribocil-C treatment groups (60 and 120 mg kg21 ribocil-C) demonstrate a dose-dependent reduction in bacterial burden of 1.87 and 3.29 log10[CFU per g spleen] reduction respectively versus shamtreated mice, without mortality or gross effects of toxicity observed[2].
[1]. Wang H, et al. Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch DisruptRiboflavin Homeostasis in an Infectious Setting. Cell Chem Biol. 2017 May 18;24(5):576-588. [2]. Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015 Oct 29;526(7575):672-7.
Animal experiment: | DBA/2J mice are infected by intraperitoneal injectionwith Escherichia coli strain MB5746 (5×104 CFU per mouse) and treated by subcutaneous injection with Ribocil-C (30, 60, 120 mg/kg) or ciprofloxacin (0.5mg/kg) three times over a 24 h infection period. Spleens are aseptically collected from five mice per group and the reduction of log[CFU per g spleen tissue] is calculated on the basis of bacterial burden in spleens of the vehicle-treated (10% DMSO) control group[2]. |
References: [1]. Wang H, et al. Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch DisruptRiboflavin Homeostasis in an Infectious Setting. Cell Chem Biol. 2017 May 18;24(5):576-588. | |
| Cas No. | 1825355-56-3 | SDF | |
| Canonical SMILES | O=C1C=C(C2=CC=CS2)NC([C@H]3CCCN(CC4=CN(C5=NC=CC=N5)C=N4)C3)=N1 | ||
| Formula | C21H21N7OS | M.Wt | 419.5 |
| الذوبان | DMSO : ≥ 24.6 mg/mL (58.64 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3838 mL | 11.919 mL | 23.8379 mL |
| 5 mM | 476.8 μL | 2.3838 mL | 4.7676 mL |
| 10 mM | 238.4 μL | 1.1919 mL | 2.3838 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *